Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) FCF Margin (2020 - 2026)

Neuroone Medical Technologies filings provide 12 years of FCF Margin readings, the most recent being 57.18% for Q1 2026.

  • On a quarterly basis, FCF Margin fell 5290.0% to 57.18% in Q1 2026 year-over-year; TTM through Mar 2026 was 77.84%, a 819.0% increase, with the full-year FY2025 number at 32.09%, up 29030.0% from a year prior.
  • FCF Margin hit 57.18% in Q1 2026 for Neuroone Medical Technologies, up from 109.13% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 1383.43% in Q3 2022 to a low of 9061.09% in Q1 2022.
  • Median FCF Margin over the past 5 years was 287.63% (2024), compared with a mean of 1350.79%.
  • Biggest five-year swings in FCF Margin: tumbled -261163bps in 2022 and later soared 826156bps in 2023.
  • Neuroone Medical Technologies' FCF Margin stood at 3057.95% in 2022, then soared by 87bps to 393.45% in 2023, then soared by 101bps to 5.61% in 2024, then plummeted by -2046bps to 109.13% in 2025, then soared by 48bps to 57.18% in 2026.
  • The last three reported values for FCF Margin were 57.18% (Q1 2026), 109.13% (Q4 2025), and 56.05% (Q3 2025) per Business Quant data.